Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, adult
Stage/Subtype:  recurrent adult soft tissue sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 46 for your search:
Start Over
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Phase: Phase III
Type: Treatment
Age: 15 and over
Trial IDs: ALDOXORUBICIN-P3-STS-01, NCI-2014-00753, NCT02049905
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SARC023, NCI-2014-02429, NCT02008877
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Bevacizumab in Treating Patients With Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 04S1, NCI-2013-01399, NCT00288015
Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0192, NCI-2013-01452, 090192, P09512, 8463, NCT00942877
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, MUSC 101644, MUSC CTO 101644, PAZ115785, PZP115785, NCT01593748
Alisertib in Treating Patients with Advanced or Metastatic Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091102, NCI-2012-01991, CALGB-A091102, CDR0000737403, NCT01653028
Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC016, NCI-2014-00697, NCT01661283
Cabozantinib-S-Malate in Treating Patients with Refractory Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0044, NCI-2012-03124, 09-25-0099, 121088, 130044, P121088, P9284_A07PAMDREVW01, 9284, NCT01755195
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients with Metastatic Sarcoma Stable on Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201309108, NCI-2013-01842, NCT01986829
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 13S02, NCI-2013-02278, ONC-2013-129, STU00087654, NCT02048722
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase: Phase II
Type: Treatment
Age: 12 and over
Trial IDs: SARC028, NCI-2015-00320, NCT02301039
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Metastatic Soft Tissue and Bone Sarcomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14S03, NCI-2014-02583, STU00200112, NCT02357810
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and over
Trial IDs: 09-090, NCI-2010-01242, NCT01099644
Start Over